ETODOLAC 300 MG
ETODOLAC : 300 MG · DIN 02231967 · APOTEX INC
Health Canada status: APPROVED
What is ETODOLAC?
ETODOLAC 300 MG contains ETODOLAC : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02231967, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 09-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02231967 |
|---|---|
| Brand name | ETODOLAC |
| Generic / active ingredient | ETODOLAC : 300 MG |
| Manufacturer | APOTEX INC |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | M01AB08 ETODOLAC |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 09-Apr-2021 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02231967 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2231967 |
| Brand name | ETODOLAC |
| Active ingredient / INN | ETODOLAC : 300 MG |
| ATC code | M01AB08 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01 |
| AHFS class | 28:08.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | APOTEX INC |
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code M01AB08 ETODOLAC. 0 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ETODOLAC | 200 MG | CAPSULE | AA PHARMA INC | DORMANT | DIN 02232317 |
| ETODOLAC | 200 MG | CAPSULE | APOTEX INC | APPROVED | DIN 02231965 |
| ETODOLAC | 300 MG | CAPSULE | AA PHARMA INC | DORMANT | DIN 02232318 |
| GEN-ETODOLAC 200MG | 200 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02239319 |
| GEN-ETODOLAC 300MG | 300 MG | CAPSULE | GENPHARM ULC | CANCELLED POST MARKET | DIN 02239320 |
| NOVO-ETODOLAC 200 MG | 200 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02242205 |
| NOVO-ETODOLAC 300 MG | 300 MG | CAPSULE | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02242206 |
| TARO-ETODOLAC | 300 MG | CAPSULE | TARO PHARMACEUTICALS INC | CANCELLED POST MARKET | DIN 02242915 |
| TARO-ETODOLAC 200 MG | 200 MG | CAPSULE | TARO PHARMACEUTICALS INC | CANCELLED POST MARKET | DIN 02242914 |
| ULTRADOL - CAP 200MG | 200 MG | CAPSULE | PROCTER & GAMBLE PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02142023 |
How much does ETODOLAC cost around the world?
ETODOLAC is listed on 2 national price registers Nexara tracks, across 23 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 4 | 22 | 03 Sep 2026 |
| Saudi Arabia | public | 1 | 1 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.